Impact of growth hormone treatment on children’s height

Background The use of growth hormone (GH) is a routinetreatment for growth hormone deficiency (GHD), small forgestational age (SGA), and Turner syndrome (TS). During thetreatment, height measurement at regular intervals is a vital stepto assess success. To date, there have been no previous studieson GH treatment in Dr. Soetomo Hospital, Surabaya, the referralhospital in East Indonesia.Objective To compare body height between pre- and post-growthhormone treatment in pediatric patients.Method This study was a non-randomized, pre-post clinical trialperformed at Dr. Soetomo Hospital, Surabaya. The prospectivecohort was accessed during January 2008-June 2013. Theinclusion criteria was GH treatment for more than 3 months.Clinical data on GH treatment, including diagnosis, age, heightpre-and post-treatment, height gain, duration of treatment, andparental satisfaction were collected. Two-tailed, paired T-test andPearson’s test were used for statistical analyses.Result Nineteen patients underwent GH treatment during thestudy period, but only twelve patients had complete data and wereincluded in the study. Eight subjects were female. Subjects’ meanage was 11 (range 8-15) years. Nine patients had GHD, 2 hadTS, and 1 had SGA. Mean pre-treatment height was 121.05 cm,while mean post-treatment height was 130.5 cm. Mean durationof treatment was 10.5 (range 3-30) months. Mean height gainwas 0.8 cm/month in GHD and SGA cases, and 0.78 cm/monthfor the TS cases. Eleven parents reported satisfaction with theresults of GH treatment in their children. There is significantdiffrent between pre- and post-treatment (P=0.001). Pearson’scorrelation test (r=0.90) revealed a strong correlation betweengrowth hormone treatment and height gain.Conclusion Growth hormone treatment has impact on heights inGH defficiency, Turner syndrome, and small for gestational age.

Download Full-text

Low FT4 Concentrations around the Start of Recombinant Human Growth Hormone Treatment: Predictor of Congenital Structural Hypothalamic-Pituitary Abnormalities?

Hormone Research in Paediatrics ◽

10.1159/000486033 ◽

2018 ◽

Vol 89 (2) ◽

pp. 98-107 ◽

Cited By ~ 5

Author(s):

Laura van Iersel ◽

Hanneke M. van Santen ◽

Gladys R.J. Zandwijken ◽

Nitash Zwaveling-Soonawala ◽

Anita C.S. Hokken-Koelega ◽

...

Keyword(s):

Growth Hormone ◽

Growth Hormone Treatment ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Hormone Treatment ◽

Hormone Deficiency ◽

Pituitary Hormone ◽

Gh Treatment ◽

Central Hypothyroidism ◽

Pituitary Disease

Background: Growth hormone (GH) treatment may unmask central hypothyroidism (CeH). This was first observed in children with GH deficiency (GHD), later also in adults with GHD due to acquired “organic” pituitary disease. We hypothesized that newly diagnosed CeH in children after starting GH treatment for nonacquired, apparent isolated GHD points to congenital “organic” pituitary disease. Methods: Nationwide, retrospective cohort study including all children with nonacquired GHD between 2001 and 2011 in The Netherlands. The prevalence of CeH, hypothalamic-pituitary (HP) abnormalities, and neonatal congenital hypothyroidism screening results were evaluated. Results: Twenty-three (6.3%) of 367 children with apparent isolated GHD were prescribed LT4 for presumed CeH within 2 years after starting GH treatment. Similarly to children already diagnosed with multiple pituitary hormone deficiency, 75% of these 23 had structural HP abnormalities. In children not prescribed LT4, low pre- or post-GH treatment FT4 concentrations were also associated with structural HP abnormalities. Neonatal screening results of only 4 of the 23 children could be retrieved. Conclusion: In children with nonacquired, apparent isolated GHD, a diagnosis of CeH after, or a low FT4 concentration around the start of GH treatment, is associated with congenital structural HP abnormalities, i.e., “organic” pituitary disease. Neonatal values could not be judged reliably.

Download Full-text

Accurate Long-Term Prediction of Height during the First Four Years of Growth Hormone Treatment in Prepubertal Children with Growth Hormone Deficiency or Turner Syndrome

Hormone Research in Paediatrics ◽

10.1159/000339468 ◽

2012 ◽

Vol 78 (1) ◽

pp. 8-17 ◽

Cited By ~ 12

Author(s):

Michael B. Ranke ◽

Anders Lindberg ◽

Mathias Brosz ◽

Stefan Kaspers ◽

Jane Loftus ◽

...

Keyword(s):

Growth Hormone ◽

Growth Hormone Deficiency ◽

Turner Syndrome ◽

Growth Hormone Treatment ◽

Hormone Treatment ◽

Hormone Deficiency ◽

Prepubertal Children ◽

Term Prediction ◽

Long Term Prediction

Download Full-text

KIGS demographic studies

Problems of Endocrinology ◽

10.14341/probl11997 ◽

1993 ◽

Vol 39 (5) ◽

pp. 68-73

Author(s):

K. Albertson-Wikland

Keyword(s):

Growth Hormone ◽

Growth Hormone Treatment ◽

Hormone Treatment ◽

Hormone Deficiency ◽

Healthy Children ◽

Growth Study ◽

Duration Of Treatment ◽

International Growth ◽

Idiopathic Disease ◽

Organic Lesions

The eighth kigs report (international growth study by Kabi Pharmacy) is based on an analysis of the treatment outcomes of 7,083 children from 18 countries. Of these, 3380 had idiopathic growth hormone deficiency (IGN), 1111 - IGN due to organic lesions and 2592 - other causes of stunting. All the children were at different schemes of injection of growth hormone. The duration of treatment in idiopathic DISEASE averaged 3.5 years, in organic disorders-4 years, with other types of stunting-3.3 years. At the beginning of treatment, all children had low growth: -2.7 SDS (Tanner standards) in idiopathic GAMES, -2.2 SDS in organic GAMES (-1.75 SDS in brain tumors, -1.8 SDS in leukemia), -2.9 SDS with other types of stunting. The average age of children in all groups before treatment was about 10 years. The growth rate before treatment was low compared to healthy children of the same age. In most cases (95 %) growth hormone treatment was carried out daily or 6 times a week, while the dose of the hormone administered in different countries varied significantly (from 0.4 to 0.7 u/kg per week). Subsequent analysis of the KIGS database will help to see how these differences will affect growth rates and the end result of treatment.

Download Full-text

Craniofacial Morphology in Children with Growth Hormone Deficiency and Turner Syndrome

Diagnostics ◽

10.3390/diagnostics10020088 ◽

2020 ◽

Vol 10 (2) ◽

pp. 88

Author(s):

Dorota Wójcik ◽

Iwona Beń-Skowronek

Keyword(s):

Growth Hormone ◽

Growth Hormone Deficiency ◽

Turner Syndrome ◽

Orthodontic Treatment ◽

Growth Hormone Treatment ◽

Hormone Treatment ◽

Craniofacial Morphology ◽

Hormone Deficiency ◽

Craniofacial Growth ◽

Craniofacial Features

The review aims to collect and demonstrate recent knowledge about craniofacial morphology in growth hormone (GH)-deficient children and children with Turner syndrome. The review describes also the effects of growth hormone treatment on craniofacial morphology of children with growth hormone deficiency and Turner syndrome. Regardless of the disorder it accompanies, short stature is associated with similar craniofacial features characteristic of all short-statured children. Characteristic craniofacial features involve lesser dimensions of the cranial base and mandibular length, proportionately smaller posterior than anterior facial height, retrognathic face, and posterior rotation of the mandible. We also analyze orthodontic treatment in children affected by disorders associated with GH deficiency or provided with growth hormone treatment in the aspect of craniofacial growth. Recent publications show also the connection between growth hormone receptor polymorphism and craniofacial growth. Specialists and orthodontists treating short-statured children must be aware of the results of studies on craniofacial morphology and educate themselves on the topic of craniofacial growth in children with short stature. Moreover, knowledge of the influence of GH therapy on growth of craniofacial structures is necessary to decide the proper timing and planning of orthodontic treatment.

Download Full-text